AZoNetwork UK Ltd.
|
Professor Volker Rasche
Prof. Rasche has worked in the field of medical imaging over the last 25 years. He is a renown physicist for developing new imaging methods for clinical and preclinical cardiovascular imaging applications.
After 15 years with industrial research and a position as visiting scientist at Harvard Medical School, he picked up a full professorship for experimental cardiovascular imaging at the University of Ulm.
|
Dr. Thomas Basse
| Thomas joined Bruker in 2014 as an application scientist and is now the Product Specialist MRI at Bruker. Previously, he studied Physics at the University of Würzburg where he graduated in 2012. During his time in Würzburg, Thomas focused on the application of 19F MRI in fields of neurology and oncology.  |
Seminar overview:
Prof. Rasche will begin by explaining what in ovo MRI imaging involves. For example he will describe a special cooling technique he and his team developed to prevent the embryo moving during data acquisition to enable high quality data.
The main focus of the webinar will be the importance of non-invasively monitoring the biodistribution of injected contrast-agent-labelled compounds and how in ovo MRI can be applied to achieve this.
Using the technique, contrast agents can be injected systemically and then longitudinally monitored to assess their biodistribution.
This enables a stepwise approach to testing, where only those compounds that appear promising in the in ovo model will be selected for final testing in small animal models on their 11.7 Tesla BioSpec.
In ovo MRI provides an efficient testing technique to determine promising compounds and therefore minimizes the number of necessary animal experiments.
Furthermore, eggs are readily available and often cheap in comparison to research animals.
Since the embryonic phase is immunodeficient, cells from different tissues and species can easily be transplanted and studied, including human cell lines.
Recently, Prof. Rasche and his team used in ovo MRI to compare the biodistribution of an off-the-shelf conventional contrast agent with that of a dedicated polymer-based contrast agent developed by the Max Planck Institute in Lyon.
The experiment clearly showed that the polymer-based agent stayed in tumors longer than the conventional agent did, thereby proving the efficacy of the in ovo model for assessing the biodistribution of such agents with MRI.
Many oncologists are also using the CAM model to investigate tumor volume and size. Another promising application of in ovo MRI may therefore be quantification of the progression or regression of tumors in response to therapy.
Who Should Attend?
The webinar will be of interest to anybody using MR systems for oncology research, ranging from technicians through to bio-engineers, biological researchers and physicians.
|
.png)
No hay comentarios:
Publicar un comentario